作者在心脏外科手术病人中观察了HBIG预防非甲非乙型肝炎的情况。手术病人的年龄在15—65岁之间,无肝炎病史,无滥用酒精、药物及对血制品过敏史,并随机分成对照组和HBIG治疗组。治疗组病人入院后及术后当天各注射5mlHBIG,并对术后输血或血制品的病人重复注射,每个病人平均输血量为5.5单位,所输血液皆为HBsAg阴性,SGPT水平在30u/L以下。术前(治疗组为首剂HBIG前)及术后1、7和14天各采血一次,此后从第6周到 The authors looked at HBIG prophylaxis of non-A, non-B hepatitis in cardiac surgery patients. Patients aged 15-65 years old, no history of hepatitis, no abuse of alcohol, drugs and allergies to blood products, and were randomly divided into control group and HBIG treatment group. The patients in the treatment group were injected with 5 ml HBIG on the day after and after the operation, and the patients were transfused or the blood products were injected repeatedly. The average blood transfusion of each patient was 5.5 units. All the blood transfusion was negative for HBsAg and the SGPT level was 30u / L the following. Preoperative (the first dose of HBIG in the treatment group) and the second, seventh and fourteenth days postoperatively